Ozempic, the weight loss wonder drug that took the world by storm last year, prompted many hedge fund managers to ramp up bets that ResMed’s shares were heading for a cliff.

Veteran short seller Sean Fenton took the opposite approach and bought more shares in late 2023. His bet paid off – so far this year, the ASX-listed medical technology firm has soared more than 30 per cent.